MustGrow Biologics Corp. (TSXV: MGRO) has appointed Kevin Helash as Chief Executive Officer, effective November 1, 2026, marking a significant leadership transition for the Saskatoon-based biological agriculture company. Helash brings prior CEO experience at Biotalys, Marrone Bio Innovations, and Agrinos, as well as senior roles at Agrium Inc., now Nutrien. The appointment coincides with internal role changes for two existing executives and a grant of stock options to the incoming CEO. Investors may be watching how the new leadership team accelerates commercialisation of the company's flagship product, TerraSante™.

Key Points

  • MustGrow Biologics Corp. (TSXV: MGRO | OTCQB: MGROF | FSE: 0C0)
  • Kevin Helash appointed CEO effective November 1, 2026, succeeding Corey Giasson who moves to Chief Operating Officer
  • Helash granted 250,000 stock options exercisable until November 1, 2033, vesting in five tranches of 50,000
  • Investors may monitor progress on TerraSante™ sales growth and the Bayer AG strategic relationship under the new leadership structure

Helash's Agriculture Industry Background and Track Record

Kevin Helash arrives at MustGrow with a career spanning major agricultural organisations. He previously served as CEO of Biotalys, Marrone Bio Innovations, and Agrinos. At Agrium Inc., now Nutrien, the release states he built and led Canada's largest agricultural retail organisation and held senior responsibilities in global wholesale fertilizer. At Marrone Bio Innovations, he led a business transformation that culminated in a US$235 million merger with Bioceres Crop Solutions in 2022. Chairman Brad Munro cited Helash's commercialisation experience and strategic partnership development as key reasons for the appointment.

Internal Leadership Restructuring at MustGrow

Alongside the CEO appointment, MustGrow announced two concurrent executive role changes. Corey Giasson, who previously held the CEO position, transitions to Chief Operating Officer, retaining focus on internal operations, production, and commercialisation support. Colin Bletsky moves into the role of Chief Commercial Officer, maintaining responsibility for product sales and global market development. The announcement describes the restructuring as designed to support the company's ongoing development and commercialisation activities, positioning the leadership team around distinct operational and commercial functions.

Stock Option Grant Tied to Helash's Appointment

In connection with the appointment, MustGrow has granted Helash an aggregate of 250,000 stock options under the company's Equity Incentive Plan. Each option entitles the holder to acquire one common share until November 1, 2033. The options vest in five equal tranches of 50,000, with the first tranche vesting on November 1, 2026 and subsequent tranches vesting on each of the four following anniversaries. The company noted that the grant remains subject to acceptance by the TSX Venture Exchange. The company did not disclose the exercise price in the announcement.